BioNTech SE: Lackluster Financials And Uncertainties In Product Pipeline-Hold
We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.
Berenberg Bank Remains a Buy on BioNTech SE (BNTX)
Berenberg Bank analyst Harry Gillis maintained a Buy rating on BioNTech SE (BNTX – Research Report) yesterday and set a price target of ...
Morgan Stanley Sticks to Its Buy Rating for BioNTech SE (BNTX)
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.
ETF Daily News5d
Analysts Set BioNTech SE (NASDAQ:BNTX) Price Target at $142.72
BioNTech (NASDAQ:BNTX – Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the ...
3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection
How expensive is the stock market right now? BioNTech (NASDAQ: BNTX) vaulted into the spotlight in 2020 when Pfizer teamed up ...
Morningstar4d
BioNTech SE ADR BNTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Yahoo Finance3d
BioNTech SE (BNTX)
Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.